A Pharmacokinetic-Pharmacodynamic Model for Predicting the Impact of CYP2C9 and VKORC1 Polymorphisms on Fluindione and Acenocoumarol During Induction Therapy

By Verstuyft Céline   Delavenne Xavier  

Clinical Pharmacokinetics, Vol. 51, Iss. 1, 2012-01 ,pp. : 41-53

Adis International

Access to resources Recommend Favorite

Prediction of In Vivo Drug-Drug Interactions from In Vitro Data: Factors Affecting Prototypic Drug-Drug Interactions Involving CYP2C9, CYP2D6 and CYP3A4

By Brown Hayley S.   Galetin Aleksandra   Hallifax David   Houston J. Brian  

Clinical Pharmacokinetics, Vol. 45, Iss. 10, 2006-01 ,pp. : 1035-1050

Adis International

Access to resources Recommend Favorite

Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol

By van den Bongard H.J.G. Desirée   Sparidans Rolf W.   Critchley David J.P.   Beijnen Jos H.   Schellens Jan H.M.  

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 151-158

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenetic Prediction of Individual Variability in Drug Response Based on CYP2D6, CYP2C9 and CYP2C19 Genetic Polymorphisms

By  

Current Drug Metabolism, Vol. 15, Iss. 7, 2014-09 ,pp. : 711-718

Bentham Science Publishers

Access to resources Recommend Favorite

Prediction of drug‐drug interactions using physiologically‐based pharmacokinetic models of CYP450 modulators included in Simcyp software

By  

Biopharmaceutics And Drug Disposition, Vol. 39, Iss. 1, 2018-01 ,pp. : 3-17

John Wiley & Sons Inc

Access to resources Recommend Favorite